Get started
GlycoMimetics, Inc.GlycoMimetics, Inc.GlycoMimetics, Inc.

GlycoMimetics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

GLYC trade ideas

5 Hot Biotechs to Hold Over The WeekendMy Post-FDA Over-The-Weekend Watchlist: $GLYC $ONCT $ONCY $PIRS $AGEN All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is likely that we see a gap up on Monday and a solid downtrend from there. Like and follow for more biotech ideas like this :) Happy Trading! Remember that these are biotech stocks and there are no guarantees in this sector. Proceed with caution!
NASDAQ:GLYCLong
by CobraTrader13
2
$GLYC Releases Trial Data For Cancer Treatment On The 10thFundamental Analysis: GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-1359, has undergone phase one safety trials, and the data from these trials will be presented at AACR on April 10, 2021. Technical Analysis $GLYC is in a heavy buy zone and is forming the bullish double bottom pattern. In addition to that, the MACD has just crossed. My Outlook I am anticipating a steady rise this week as buyers trickle in anticipation of this data release. The share price could easily be $3.70 by Friday as we bounce from this. Since this is a phase one data release, it would be possible to play the post-release here as well. Because the drug is a cancer treatment, if the data is good, people will get extremely excited. With a market cap of $163M, there is no telling how high the price could soar after the release. Good Luck! If you like bio ideas like this, follow @CobraTrader13. He posts a biotech watchlist every week, with plenty of FDA hype plays like this one.
NASDAQ:GLYCLong
by Investor4321
WORKED OFF THE FIRST LEGTHIS BIOTECH HAD A MONSTER MOVE FROM 5 TO 17 BEFORE COMING BACK TO EARTH. IT HAS SOME HIGH OCTANE PARTNERS LIKE PFIZER AND IS IN SEVERAL CLINICAL TRIALS. VOLUME DECLINED ON THE SELLOFF AND THE STOCK HAS BEEN RIDING THE 50 DAY m.a.AND JUST CLOSED ABOVE THE 13 DAY. THE OPTIONS HAVE ZERO OPEN INTEREST OR LIQUIDITY. i AM ALREADY LONG FROM $12 AND MISSED MY OPPORTUNITY TO AVERAGE DOWN. I'D BE SURPRISED IF IT DOESN'T TEST $13.41. THE HIGH CLOSE IS $14 AND THEN WHO KNOWS....
NASDAQ:GLYCLong
by GreatWizeOz